Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	VBI Vaccines	Bicycle Therapeutics	Veru	Chimerix	Chinook Therapeutics
Symbol	NASDAQ:VBIV	NASDAQ:BCYC	NASDAQ:VERU	NASDAQ:CMRX	NASDAQ:KDNY
Price Information
Current Price	$2.78	$31.75	$7.81	$8.15	$16.26
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.5	1.3	1.4	1.7	1.4
Analysis Score	3.6	3.5	3.5	4.5	3.5
Community Score	3.2	2.4	2.9	2.4	2.8
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.8	0.0	1.7	0.0
Earnings & Valuation Score	0.0	0.0	0.6	0.0	0.6
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$7.00	$42.00	$19.20	$18.80	$30.33
% Upside from Price Target	151.80% upside	32.28% upside	145.84% upside	130.67% upside	86.55% upside
Trade Information
Market Cap	$706.66 million	$733.11 million	$561.63 million	$702.62 million	$689.15 million
Beta	2.14	-0.21	0.71	1.88	0.26
Average Volume	6,006,340	165,184	3,627,519	1,023,129	184,214
Sales & Book Value
Annual Revenue	$2.22 million	$13.80 million	$42.59 million	$12.52 million	$17.26 million
Price / Sales	318.32	53.12	13.19	56.12	39.93
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.50 per share	$5.27 per share	$0.43 per share	$1.79 per share	$4.07 per share
Price / Book	5.56	6.02	18.16	4.55	4.00
Profitability
Net Income	$-54,810,000.00	$-30,610,000.00	$-18,970,000.00	$-112,580,000.00	$-82,370,000.00
EPS	($0.46)	($2.77)	($0.11)	($0.86)	($5.15)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-2,837.73%	-321.26%	-44.55%	-321.31%	-215.80%
Return on Equity (ROE)	-36.69%	-42.73%	-23.72%	-36.57%	-112.72%
Return on Assets (ROA)	-28.29%	-28.77%	-13.80%	-33.53%	-21.36%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.10%	0.13%	N/A	N/A	N/A
Current Ratio	9.06%	9.63%	1.83%	12.18%	11.27%
Quick Ratio	8.95%	9.63%	1.38%	12.18%	11.27%
Ownership Information
Institutional Ownership Percentage	52.13%	42.68%	23.32%	45.41%	N/A
Insider Ownership Percentage	10.50%	26.30%	26.10%	9.00%	5.90%
Miscellaneous
Employees	127	87	339	54	43
Shares Outstanding	254.20 million	23.09 million	71.91 million	86.21 million	42.38 million
Next Earnings Date	5/12/2021 (Estimated)	8/4/2021 (Estimated)	5/12/2021 (Confirmed)	8/9/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Optionable	Not Optionable	Optionable	Optionable	Optionable

Source	Headline
	Financial Contrast: Chinook Therapeutics (NASDAQ:KDNY) & AC Immune (NASDAQ:ACIU) americanbankingnews.com - May 8 at 11:14 AM
	Chinook Therapeutics, Inc. (NASDAQ:KDNY) to Post FY2022 Earnings of ($3.64) Per Share, Cantor Fitzgerald Forecasts americanbankingnews.com - May 7 at 9:05 AM
	Chinook Therapeutics Inc (KDNY) investing.com - May 1 at 8:49 AM
	Chinook Therapeutics (NASDAQ:KDNY) Shares Up 7.6% americanbankingnews.com - April 29 at 3:58 PM
	Chinook Therapeutics (NASDAQ:KDNY) Sees Large Volume Increase americanbankingnews.com - April 28 at 2:44 PM
	At what point in time would I choose to purchase Chinook Therapeutics, Inc. (NASDAQ:KDNY) stock? stocksregister.com - April 28 at 2:03 PM
	Chinook Therapeutics, Inc. (NASDAQ:KDNY) Stock Forecast 2021: $40 Per Share With Bullish Signs marketingsentinel.com - April 27 at 9:24 AM
	Cantor Fitzgerald Comments on Chinook Therapeutics, Inc.'s FY2021 Earnings (NASDAQ:KDNY) americanbankingnews.com - April 21 at 7:28 AM
	Chinook Therapeutics (NASDAQ:KDNY) Trading 6.4% Higher americanbankingnews.com - April 15 at 1:18 PM
	Chinook Therapeutics, Inc. (NASDAQ:KDNY) Receives Average Recommendation of "Buy" from Analysts americanbankingnews.com - April 15 at 10:48 AM
	Chinook Therapeutics Presents Data During the ISN World Congress of Nephrology 2021 finance.yahoo.com - April 15 at 9:15 AM
	Q1 2021 EPS Estimates for Chinook Therapeutics, Inc. (NASDAQ:KDNY) Lowered by Analyst americanbankingnews.com - April 15 at 6:32 AM
	Chinook: Q4 Earnings Snapshot \| Raleigh News & Observer newsobserver.com - April 7 at 6:31 PM
	Chinook: Q4 Earnings Snapshot ourmidland.com - April 7 at 6:31 PM
	Chinook Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results finance.yahoo.com - April 7 at 6:31 PM
	Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of ... apnews.com - April 7 at 1:30 PM
	Chinook Therapeutics Announces First Patient Dosed in Phase 2 AFFINITY Basket Study of Atrasentan in Proteinuric Glomerular Diseases finance.yahoo.com - April 7 at 8:30 AM
	Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger finance.yahoo.com - April 5 at 8:35 AM
	Chinook (KDNY) Surges 7%: Is This an Indication of Further Gains? finance.yahoo.com - March 31 at 2:33 PM
	Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology ... apnews.com - March 30 at 6:30 PM
	Chinook Therapeutics Announces Upcoming Data Presentations at ISN World Congress of Nephrology 2021 and 58th ERA-EDTA Congress finance.yahoo.com - March 30 at 6:30 PM
	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of ... apnews.com - March 16 at 10:09 AM
	Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 ALIGN Study of Atrasentan for Patients with IgA Nephropathy finance.yahoo.com - March 16 at 10:09 AM
	Chinook Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell nasdaq.com - March 5 at 5:57 PM
	Chinook Therapeutics and Evotec Announce Strategic Collaboration to Discover and Develop Novel ... apnews.com - March 2 at 1:30 AM

Date	Company	Brokerage	Action
2/25/2021	VBI Vaccines	Jefferies Financial Group	Initiated Coverage
8/27/2020	VBI Vaccines	Oppenheimer	Reiterated Rating
8/26/2020	VBI Vaccines	Raymond James	Upgrade
6/29/2020	VBI Vaccines	BMO Capital Markets	Reiterated Rating
3/6/2020	VBI Vaccines	Canaccord Genuity	Reiterated Rating
5/7/2021	Bicycle Therapeutics	HC Wainwright	Boost Price Target
5/7/2021	Bicycle Therapeutics	Piper Sandler	Boost Price Target
4/26/2021	Bicycle Therapeutics	JMP Securities	Initiated Coverage
1/20/2021	Bicycle Therapeutics	Cantor Fitzgerald	Boost Price Target
11/14/2019	Bicycle Therapeutics	Roth Capital	Initiated Coverage
9/11/2019	Bicycle Therapeutics	The Goldman Sachs Group	Upgrade
6/17/2019	Bicycle Therapeutics	Piper Jaffray Companies	Initiated Coverage
12/14/2020	Veru	Brookline Capital Management	Boost Price Target
3/20/2019	Veru	CIBC	Initiated Coverage
5/5/2021	Chimerix	Maxim Group	Initiated Coverage
4/12/2021	Chimerix	Jonestrading	Reiterated Rating
3/31/2021	Chimerix	Wedbush	Initiated Coverage
5/9/2019	Chimerix	Cowen	Reiterated Rating
3/6/2019	Chimerix	Citigroup	Lower Price Target
3/22/2021	Chinook Therapeutics	Bloom Burton	Reiterated Rating
11/2/2020	Chinook Therapeutics	Evercore ISI	Initiated Coverage
10/7/2020	Chinook Therapeutics	SVB Leerink	Initiated Coverage
10/6/2020	Chinook Therapeutics	William Blair	Reiterated Rating

(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources